Wall Street brokerages predict that Denali Therapeutics Inc. (NASDAQ:DNLI) will report earnings per share (EPS) of ($0.42) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Denali Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.70) and the highest estimate coming in at ($0.05). Denali Therapeutics posted earnings of ($0.56) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 25%. The company is scheduled to report its next earnings report on Friday, August 6th.
On average, analysts expect that Denali Therapeutics will report full year earnings of ($1.46) per share for the current fiscal year, with EPS estimates ranging from ($2.69) to $0.02. For the next financial year, analysts anticipate that the business will post earnings of ($2.15) per share, with EPS estimates ranging from ($3.12) to ($1.17). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Denali Therapeutics.
Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Sunday, May 2nd. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.24). The business had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $31.62 million. Denali Therapeutics had a negative net margin of 968.59% and a negative return on equity of 39.19%. Denali Therapeutics’s revenue for the quarter was up 119.4% on a year-over-year basis.
Shares of Denali Therapeutics stock traded down $2.69 on Tuesday, reaching $55.62. The stock had a trading volume of 727,261 shares, compared to its average volume of 570,040. The company has a 50 day moving average price of $56.82 and a 200 day moving average price of $64.76. Denali Therapeutics has a 1 year low of $21.41 and a 1 year high of $93.94. The stock has a market capitalization of $6.74 billion, a P/E ratio of -25.17 and a beta of 2.00.
In related news, COO Alexander O. Schuth sold 10,000 shares of the business’s stock in a transaction on Thursday, February 4th. The shares were sold at an average price of $67.84, for a total value of $678,400.00. Following the completion of the transaction, the chief operating officer now directly owns 10,686 shares in the company, valued at approximately $724,938.24. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Alexander O. Schuth sold 1,468 shares of the business’s stock in a transaction on Tuesday, February 9th. The shares were sold at an average price of $74.80, for a total transaction of $109,806.40. Following the completion of the transaction, the chief operating officer now owns 10,686 shares of the company’s stock, valued at $799,312.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,449,495 shares of company stock valued at $158,540,085. Company insiders own 19.30% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE increased its holdings in Denali Therapeutics by 180.1% in the 4th quarter. US Bancorp DE now owns 395 shares of the company’s stock worth $33,000 after acquiring an additional 254 shares in the last quarter. Exchange Traded Concepts LLC purchased a new stake in Denali Therapeutics in the 4th quarter worth $42,000. HM Payson & Co. purchased a new stake in Denali Therapeutics in the 3rd quarter worth $45,000. Meeder Asset Management Inc. purchased a new stake in Denali Therapeutics in the 1st quarter worth $139,000. Finally, Bartlett & Co. LLC purchased a new stake in Denali Therapeutics in the 4th quarter worth $168,000. 68.15% of the stock is owned by institutional investors.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.